Skip to main content

REVIEW article

Front. Genome Ed.
Sec. Genome Editing in Human Health and Disease
Volume 6 - 2024 | doi: 10.3389/fgeed.2024.1509924
This article is part of the Research Topic CRISPR Medicine Conference 2024 View all articles

Advances in CRISPR-Cas Technology and its applications: Revolutionising precision medicine

Provisionally accepted
Sarkar Sardar Azeez Sarkar Sardar Azeez 1Rahin Shareef Hamad Rahin Shareef Hamad 1Bahra Kakamin Hamad Bahra Kakamin Hamad 2Mudhir Sabir Shekha Mudhir Sabir Shekha 3*Peter Bergsten Peter Bergsten 3
  • 1 Medical Laboratory Technology department, Erbil Polytechnic University, Erbil, Iraq
  • 2 Erbil Polytechnic University, Erbil, Iraq
  • 3 Department of Medical Cell Biology, Uppsala University, Uppsala, Uppsala, Sweden

The final, formatted version of the article will be published soon.

    CRISPR-Cas (Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-associated proteins) has undergone marked advancements since its discovery as an adaptive immune system in bacteria and archaea, emerged as a potent gene-editing tool after the successful engineering of its synthetic guide RNA (sgRNA) toward the targeting of specific DNA sequences with high accuracy. Besides its DNA editing ability, furtherdeveloped Cas variants can also edit the epigenome, rendering the CRISPR-Cas system a versatile tool for genome and epigenome manipulation and a pioneering force in precision medicine. This review explores the latest advancements in CRISPR-Cas technology and its therapeutic and biomedical applications, highlighting its transformative impact on precision medicine. Moreover, the current status of CRISPR therapeutics in clinical trials is discussed. Finally, we address the persisting challenges and prospects of CRISPR-Cas technology.

    Keywords: CRISPR-Cas9, Genome editing, Epigenome modulation, cancer immunotherapy, and CRISPR in clinical trials

    Received: 11 Oct 2024; Accepted: 28 Nov 2024.

    Copyright: © 2024 Azeez, Hamad, Hamad, Shekha and Bergsten. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Mudhir Sabir Shekha, Department of Medical Cell Biology, Uppsala University, Uppsala, 753 12, Uppsala, Sweden

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.